Patient Facts Study Results Part III: SSDQA Comparison

- The anomalous longitudinal trends noted in National, Seattle, and Nationwide's data in the version of this analysis run against the previous cohort (Part II) still appear here. - Stanford, new to this version of the cohort, generally trends below the rest of the network for labs at hematology visits. This is consistent with other checks executed from this module. - Stanford also has poor data availability pre-2015, which is a known issue that is reflected in these results. - Hydroxyurea (not evaluated in prior executions of this analysis) is poorly populated at Nationwide & Lurie. National has the best population of this drug consistently across the entire time series.